Mabrix 500 IV Infusion Injection

About Mabrix 500 IV Infusion 500 mg/50 ml Injection

Mabrix 500 IV Infusion 500 mg/50 ml is a injection product of Advanced Chemical Industries PLC that contains Rituximab. It may be given alone or in combination with chemotherapy, depending on the type and stage of the disease.

There are 2 brands of Rituximab listed in Bangladesh. The lowest listed price is Mabrix 100 iv 10 mg/ml Injection at ৳ 13000 per unit.

What is Mabrix 500 IV Infusion 500 mg/50 ml Injection?

Made by Advanced Chemical Industries PLC, Mabrix 500 IV Infusion is a injection whose active ingredient is Rituximab. Mabrix 500 IV Infusion is a prescription injection containing Rituximab, a type of medicine called a cytotoxic immunosuppressant. Because it affects the immune system and can cause serious reactions, it is given in a hospital or clinic setting by healthcare professionals. Use it only as your doctor directs.

Uses of Mabrix 500 IV Infusion

It may be given alone or in combination with chemotherapy, depending on the type and stage of the disease. It is also used as maintenance therapy in some patients who respond to initial treatment. Mabrix 500 IV Infusion is used to treat non-Hodgkin's lymphoma, a cancer of the lymphatic system. Your doctor will decide if it is suitable for you.

How to use Mabrix 500 IV Infusion

The dose, infusion rate and course are decided by the doctor and may be adjusted based on your response and side effects. Do not inject it yourself unless a doctor has shown you how. Mabrix 500 IV Infusion is given as an injection by a healthcare professional. Swallow the injection with water unless your doctor or pharmacist advises otherwise. If you miss a dose, ask your doctor or pharmacist what to do. Do not change the dose or stop early without asking your doctor.

Side effects of Mabrix 500 IV Infusion

Common side effects include fever, chills, itching, skin rash, flushing, low blood pressure, headache, and tiredness. Some patients may experience hepatitis B reactivation. More serious effects can include breathing difficulties, heart problems, low blood counts, and liver problems. Contact your doctor if you notice anything unusual after taking it. Tell your doctor promptly if you notice any unusual symptoms during or after the infusion.

Safety and precautions

This medicine is not recommended during pregnancy unless the doctor decides the benefit outweighs the risk, and it should not be used while breastfeeding. Before receiving Mabrix 500 IV Infusion, tell your doctor if you have a history of heart disease, lung problems, or a large tumour burden, as extra monitoring may be needed. Always inform your doctor about all medicines you take and any health conditions you have. Keep out of reach of children.

Frequently asked questions

What does Mabrix 500 IV Infusion treat?

It may be given alone or in combination with chemotherapy, depending on the type and stage of the disease. It is also used as maintenance therapy in some patients who respond to initial treatment.

How is Mabrix 500 IV Infusion used?

The dose, infusion rate and course are decided by the doctor and may be adjusted based on your response and side effects. Do not inject it yourself unless a doctor has shown you how.

What should I watch for while using Mabrix 500 IV Infusion?

Common side effects include fever, chills, itching, skin rash, flushing, low blood pressure, headache, and tiredness. Some patients may experience hepatitis B reactivation.

Is Mabrix 500 IV Infusion safe for everyone?

This medicine is not recommended during pregnancy unless the doctor decides the benefit outweighs the risk, and it should not be used while breastfeeding. Before receiving Mabrix 500 IV Infusion, tell your doctor if you have a history of heart disease, lung problems, or a large tumour burden, as extra monitoring may be needed.

Indications

Non-Hodgkin's Lymphoma (NHL): Rituximab is indicated for the treatment of patients with-
  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent maintenance therapy.
  • ... Read more
Non-Hodgkin's Lymphoma (NHL): Rituximab is indicated for the treatment of patients with-
  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent maintenance therapy.
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
Chronic Lymphocytic Leukemia (CLL): Rituximab is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.

Rheumatoid Arthritis (RA): Rituximab in combination with methotrexate is indicated for the treatment of adult patients with moderately- to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Granulomatos Is With Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA): Rituximab, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) andMicroscopic Polyangiitis (MPA).

Pharmacology

Rituximab is a chimeric monoclonal antibody to CD20 antigen which regulates cell cycle initiation. It binds to the antigen on the cell surface, activating complement-dependent B-cell cytotoxicity; and to human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity.

Duration: Detectable in serum 3-6 mth after completion of therapy; B-cell recovery 6-12 mth following completion of therapy.

Dosage & Administration

Intravenous (Adult)-

Non-Hodgkin's lymphoma, Refractory or relapsed follicular lymphoma: As a single agent, 375 mg/m2 infusion once wkly, for 4 doses at an initial rate of 50 mg/hr. May increase by 50 mg/hr every 30 min. If tolerated, subsequent infusions can be started at 100 mg/hr and increased by 100 mg/hr every 30 min. Max rate: 400 mg/hr. When used with CVP (cyclophosphamide, vincristine and prednisolone) for follicular lymphoma or CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) for diffuse large B-cell lymphoma, 375 mg/m2 given on day 1 of the chemotherapy cycle after corticosteroid regimen, for up to 8 cycles. For patients who were treated with 6-8 cycles of CVP chemotherapy and have not progressed, 375 mg/m2 may be given once wkly for 4 doses, may repeat every 6 mth, for up to 16 doses. Maintenance: 375 mg/m2 given once every 3 mth (those who have responded to induction chemotherapy), once every 2 mth initiated 2 mth after the last dose of induction chemotherapy (previously untreated) for a max period of 2 yr.

Chronic lymphocytic leukaemia: 375 mg/m2, given on the day prior to chemotherapy in cycle 1, followed by 500 mg/m2 on day 1 (every 28 days) of cycles 2-6.

Rheumatoid arthritis: Given as two 1 g IV infusion doses, separated by 2 wk and in combination with methotrexate. Corticosteroids may be given before each infusion to minimise the risk and severity of infusion reactions.

Interaction

Increased risk of renal toxicity with cisplatin.

Contraindications

Hypersensitivity to murine proteins. Patients with active, severe infections. Severely immunocompromised state. Concomitant use with live viral vaccines. Lactation.

Side Effects

Reactivation of hepatitis B virus. Fever and rigors. Pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, asthenia, headache, rhinitis, thrombocytopenia, neutropenia, anaemia, abdominal pain, bowel obstruction, and perforation. Exacerbation of heart failure and angina pectoris. Reversible interstitial pneumonia and interstitial fibrosis. Depletion of immunoglobulin concentrations.

Pregnancy & Lactation

Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

Precautions & Warnings

Extensive tumour burden, pulmonary insufficiency or pulmonary tumour infiltration; history of cardiac disease. Pregnancy.

Storage Conditions

Store between 2-8° C.

Alternative brands of Rituximab

Other brands with the same generic name, cheapest first.

Mabrix 100 iv Injection

10 mg/ml

Rituximab

Advanced Chemical Industries PLC

৳ 12740 ৳ 13000 2% off per unit

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.